v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company manages its operations as a single segment focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, obesity, neuroscience, and oncology. Biohaven's CEO, as the Company's chief operating decision maker, manages and allocates resources at a consolidated level.
The CEO uses net loss that is also reported on the condensed consolidated statement of operations as net loss to assess performance and decide how to allocate resources. The measure of segment assets is reported on the condensed consolidated balance sheet as total consolidated assets. Expenditures for the addition of long-lived assets are reported on the condensed consolidated statements of cash flows as purchases of property and equipment.
Additional information about segment profit or loss and significant segment expenses is as follows:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Direct R&D program expense
BHV-4157 (Troriluzole)$7,704 $14,245 $14,626 $28,033 
BHV-2000 (Taldefgrobep Alfa)5,730 8,045 15,062 14,229 
BHV-7000 & BHV-7010 (Kv7)13,845 31,172 33,578 62,744 
BHV-2100 & BHV-2110 (TRPM3 Antagonist)
(325)6,845 (530)23,594 
BHV-8000 (TYK2/JAK1)4,142 21,216 9,312 25,589 
BHV-1300 (IgG Degrader)9,861 11,732 11,003 20,352 
BHV-1310 (IgG Degrader)15 3,612 (19)4,686 
BHV-1400 (IgA Degrader)11,709 6,737 16,846 11,597 
BHV-1600 (β1-AR AAB Degrader)(288)1,806 (99)4,809 
BHV-1510 (TROP-2)
2,465 5,384 6,502 9,873 
BHV-1530 (FGFR3)2,211 15,393 3,410 18,569 
Other R&D program expense14 1,104 63 1,615 
Preclinical research programs R&D Expense
7,730 16,398 16,279 41,933 
R&D personnel expense (excluding share-based compensation)(1)
19,421 20,490 40,433 41,627 
R&D Share-based compensation expense
11,983 13,110 30,458 48,344 
G&A personnel expense (excluding share-based compensation)(1)
5,765 6,004 11,220 12,478 
G&A Share-based compensation expense
7,181 7,702 16,992 25,530 
Other segment items (2)
15,736 20,706 30,191 37,660 
Non-operating expense (income)12,021 (13,815)11,853 (14,308)
Provision for income taxes
391 261 663 870 
Segment net loss
137,311 198,147 267,843 419,824 
Reconciliation of profit or loss
Adjustments and reconciling items
— — — — 
Consolidated net loss
$137,311 $198,147 $267,843 $419,824 
(1)    Personnel expense includes employee payroll, bonus, and employee benefits for medical care, retirement, insurances and other.
(2)    Other segment items included in Segment net loss include unallocated non-program R&D expense, legal, accounting and other professional service fees, rent and utilities expense, depreciation, and other corporate expenses.